Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
about
Current medical treatment of estrogen receptor-positive breast cancerCholecalciferol and Cancer: Is It a Big D3-eal?Evaluating the potential bioactivity of a novel compound ER1626Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivoGeographic disparities in adherence to adjuvant endocrine therapy in Appalachian women with breast cancer.Adjuvant therapy use among Appalachian breast cancer survivorsInduction of Integrin Signaling by Steroid Sulfatase in Human Cervical Cancer Cells.Aromatase inhibitor associated musculoskeletal symptoms are associated with reduced physical activity among breast cancer survivorsStatus of adjuvant endocrine therapy for breast cancer.The JACS prospective cohort study of newly diagnosed women with breast cancer investigating joint and muscle pain, aches, and stiffness: pain and quality of life after primary surgery and before adjuvant treatment.The time since last menstrual period is important as a clinical predictor for non-steroidal aromatase inhibitor-related arthralgia.Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.Sexual problems during the first 2 years of adjuvant treatment with aromatase inhibitors.Lifestyle interventions for cardiovascular risk reduction in women with breast cancer.Lipid profiles within the SABRE trial of anastrozole with and without risedronate.Early contralateral shoulder-arm morbidity in breast cancer patients enrolled in a randomized trial of post-surgery radiation therapy.Melanoma prevention using topical PBISePathways to breast cancer recurrence.Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort.Breast cancer survivorship symptom management: current perspective and future development.The Effect of Atorvastatin on Breast Cancer Biomarkers in High-Risk Women.Endocrine therapy initiation among Medicaid-insured breast cancer survivors with hormone receptor-positive tumors.Oncology providers' perspectives on endocrine therapy prescribing and management.Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update.The effect of a community-based exercise intervention on symptoms and quality of life.Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker.Adherence to long-term adjuvant hormonal therapy for breast cancer.A prospective model of care for breast cancer rehabilitation: bone health and arthralgias.Adjuvant systemic therapy in breast cancer: quo vadis?Is it best to expect the worst? Influence of patients' side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study.A prospective study of aromatase inhibitor therapy initiation and self-reported side effects.Aspirin use is associated with lower mammographic density in a large screening cohort.Persistence to 5-year hormonal breast cancer therapy: a French national population-based study.18β-glycyrrhetinic acid induces apoptosis through modulation of Akt/FOXO3a/Bim pathway in human breast cancer MCF-7 cells.Antiestrogenic effects of the fetal estrogen estetrol in women with estrogen-receptor positive early breast cancer.Opioid use among female breast cancer patients using different adjuvant endocrine therapy regimens.The impact of endocrine therapy on sexual dysfunction in postmenopausal women with early stage breast cancer: encouraging results from a prospective study.Effect of concurrent prescription antiarthralgia pharmacotherapy on persistence to aromatase inhibitors in treatment-naive postmenopausal females.Facilitating adherence to endocrine therapy in breast cancer: stability and predictive power of treatment expectations in a 2-year prospective study.Recommendations for antiresorptive therapy in postmenopausal patients with breast cancer: Marburg AIBL Guideline Evaluation Study (MAGES).
P2860
Q26795751-7C9B067C-56E3-4134-9EE6-A60BB9831A3DQ26852226-BD68CE71-FC96-4D53-B94D-FD96A81A4487Q28539181-22619F54-121E-4494-808F-59346AC372EFQ30275126-E7B371A1-FE61-479D-B26B-B1DEF0411DCAQ30275906-060F926E-FCFB-42FE-A971-5E65EEEBBAF1Q30279083-17CFAAF8-16CE-4829-A357-5C5518F2918DQ33655922-44CB9D38-26A7-4950-BA15-32480DDA65BDQ33714141-4C21C0E0-5782-443B-A033-8BABD12E54EDQ33739138-0C430A4D-6E99-4C4B-80A5-7C20D081EA64Q33826701-23FACE81-1DEA-4BED-8BE5-3762F46B040BQ34045510-6166D70B-286C-41A0-92DC-01CA39120F84Q34978227-98729533-1B91-448F-97D6-42DADE749E59Q35207952-16C2D5EE-A4F9-4391-B389-1E0C4822DC14Q35878469-3D4D7D92-7C3F-4BA4-B1B3-F7E37BB2370DQ36161292-008B78AF-AD3B-4F4F-A5D0-FACEB5ED593EQ36161318-9CD8E1C1-D588-47F7-9F60-221149B35F08Q36384802-087757CC-9214-4075-B068-0A93D89E6A44Q36702139-AEFCA37C-45A7-4077-8D2C-B1BA6E254119Q36941450-3E58842F-439C-41B0-A9B4-02A3EBEA0BAEQ36956837-292B0C97-D033-4DB3-9C4C-D6E0623A7741Q37137519-0BA69D21-BC95-45FC-B451-A977F07ADAE6Q37146389-E0C271A1-A03A-4536-96E2-FB593CF18827Q37316792-EE562E76-8C51-4E16-9A59-95BBC246B34CQ37355574-D8583C55-ECA4-413A-BBE7-F85A6F84CC7FQ37374507-2333FBD9-9E66-4A04-B231-2605BCDD03B9Q37463330-2EC73C2A-B646-46B2-8951-BB60DB9184D4Q37958054-6831E85F-577A-4C16-85EF-D9A379A6E6AAQ38001377-46F354F7-3CEA-44C0-9238-464527933090Q38364913-EE36E5A1-9109-4A12-8B11-47B63601659BQ38388524-3E3A76F2-CF0E-483F-8270-DBD0EEDB9719Q38877166-1CFE6002-0CB6-4D4D-9DD6-1481154B03E4Q39119109-8C22341D-B4D9-4924-8778-790C943FFE70Q39419032-6541C758-1416-4556-853C-55E590D72920Q39512103-863F7623-F2A3-4B50-A07E-57D615C34163Q44241461-AAD2608F-5431-4E19-A4B6-2492CB2B39C0Q44346721-B3D0FE32-0ADD-48EC-84A5-C0A46419A9FBQ45210542-336009B4-2F2C-456D-8447-A55FFB419E5BQ45732094-2ECAFF40-5DCE-4CB1-8EB8-2362DE6B1E41Q48250658-0FB96F9C-7FD3-420A-863F-BD0888995F08Q51393764-D603D10C-22E8-40CB-9351-7277415E619E
P2860
Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 20 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@en
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@nl
type
label
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@en
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@nl
prefLabel
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@en
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@nl
P2093
P2860
P1476
Aromatase inhibitor therapy: t ...... sensitive early breast cancer.
@en
P2093
Michelle Kissner
Rania Gaspo
Susan F Dent
P2860
P2888
P304
P356
10.1007/S10549-011-1351-3
P407
P577
2011-01-20T00:00:00Z